BREAKING: Moderna reaches settlement with Arbutus/Genevant — $950M up front, royalty-free license covering…
Filed with the SEC on · Summarized by InvestorsBot
BREAKING: Moderna reaches settlement with Arbutus/Genevant — $950M up front, royalty-free license covering Spikevax & infectious disease vaccine pipeline, and no future royalties for these products. $MRNA 🚨💰🧪 #BREAKING #vaccines #biotech #patents
ALERT: What this means — legal cloud cleared for Spikevax, mNEXSPIKE, mCOMBRIAX and future vaccines, giving operational certainty — BUT a $1.3B contingent payment may still be triggered depending on the Federal Circuit §1498 appeal. $MRNA ⚖️🔁 #patents #stocks #vaccines
Confirmed details — $950M noncontingent lump sum due on or before July 8, 2026. If Moderna loses/doesn’t appeal on §1498, an extra $1.3B (or prorated amount) due within 90 days; Arbutus must repay any contingent cash if decision later reversed. 🗓️📜 $MRNA #investing #legal #pharma